Jubilant Ingrevia Ltd

Jubilant Ingrev. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jubilant Ingrevia Ltd

₹ 523 -2.14%
07 May 4:02 p.m.
jubilantingrevia.com BSE: 543271 NSE : JUBLINGREA
About

Jubilant Ingrevia, a global integrated Life Science products and Innovative Solutions provider serving, Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers with our customised products and solutions that are innovative, cost-effective and conforming to excellent quality standards.

Jubilant Ingrevia’s portfolio also extends to custom research and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis. [1]

Key Points

Leadership[1]
# 40+ years of legacy in Chemicals space, started in 1978
# Global player in Pyridine + Beta, Vitamin B3 and Acetic Anhydride.
# Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies.
# Leading Low-Cost provider

Website BSE NSE
  • Market Cap ₹ 8,336 Cr.
  • Current Price ₹ 523
  • High / Low ₹ 582 / 379
  • Stock P/E 49.0
  • Book Value ₹ 140
  • Dividend Yield 0.96 %
  • ROCE 15.5 %
  • ROE 12.3 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 21.2%
  • Debtor days have improved from 115 to 39.8 days.
  • Company's working capital requirements have reduced from 106 days to 44.7 days

Cons

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Chemicals Industry: Chemicals

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
669 1,105 1,237 1,256 1,262 1,158 1,250 1,091 1,061 1,031 1,003 917
572 861 1,023 1,057 1,106 1,016 1,113 962 974 917 882 843
Operating Profit 97 245 214 199 156 141 137 129 87 114 121 74
OPM % 14% 22% 17% 16% 12% 12% 11% 12% 8% 11% 12% 8%
-10 6 7 9 7 9 7 6 8 10 8 8
Interest 9 17 11 9 10 8 9 11 10 15 16 18
Depreciation 21 31 30 30 30 31 30 29 29 32 33 34
Profit before tax 56 203 180 170 122 112 104 95 56 77 80 30
Tax % 31% 32% 32% 31% 39% 32% 33% 28% 32% 29% 28% 36%
39 138 123 117 74 76 70 68 39 55 57 19
EPS in Rs 2.42 8.67 7.69 7.35 4.68 4.80 4.42 4.27 2.43 3.44 3.60 1.21
Raw PDF
Upcoming result date: 14 May 2024

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
0 669 4,860 4,560 4,012
0 572 4,039 4,064 3,615
Operating Profit -0 97 821 496 396
OPM % 14% 17% 11% 10%
0 -10 21 30 34
Interest 0 9 46 38 59
Depreciation 0 21 120 120 128
Profit before tax -0 56 675 368 243
Tax % 0% 31% 33% 31%
-0 39 452 253 170
EPS in Rs -3.40 2.42 28.39 15.91 10.68
Dividend Payout % 0% 14% 18% 31%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -16%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 1044%
TTM: -41%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: 8%
1 Year: 22%
Return on Equity
10 Years: %
5 Years: %
3 Years: 16%
Last Year: 12%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 0 16 16 16 16
Reserves -0 1,560 1,967 2,143 2,215
0 782 469 645 941
0 882 1,200 1,255 1,058
Total Liabilities 0 3,240 3,652 4,058 4,230
0 1,727 1,728 1,775 2,064
CWIP 0 65 167 477 295
Investments 0 135 139 172 248
0 1,313 1,619 1,635 1,623
Total Assets 0 3,240 3,652 4,058 4,230

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023
0 104 587 446
0 32 -221 -475
0 -70 -410 33
Net Cash Flow 0 66 -44 3

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 262 44 40
Inventory Days 490 97 127
Days Payable 649 101 117
Cash Conversion Cycle 103 40 50
Working Capital Days 230 42 45
ROCE % 7% 30% 16%

Shareholding Pattern

Numbers in percentages

4 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
50.92% 50.92% 51.03% 51.10% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47% 51.47%
18.70% 11.11% 12.42% 11.21% 10.19% 9.24% 8.40% 7.73% 6.15% 6.30% 6.35% 6.58%
1.44% 0.81% 0.60% 0.67% 0.70% 2.36% 4.89% 5.97% 6.72% 9.18% 11.17% 13.60%
28.75% 36.97% 35.75% 36.82% 37.44% 36.72% 35.03% 34.62% 34.83% 32.22% 30.17% 27.53%
0.20% 0.20% 0.20% 0.20% 0.20% 0.20% 0.19% 0.19% 0.82% 0.82% 0.82% 0.81%
No. of Shareholders 95,2351,49,9391,81,8471,91,4771,93,8581,95,7041,86,8951,85,0621,86,2941,73,5331,62,2021,50,388

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls